Fate Therapeutics

Fate Therapeutics

Yahoo Finance • 3 days ago

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immu... Full story

Yahoo Finance • 6 days ago

Strong Buy at under $10: The highest Quant-rated bargain stocks right now

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny... Full story

Yahoo Finance • 13 days ago

Health Care had the best week vs. the S&P 500 on record

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [htt... Full story

Yahoo Finance • 24 days ago

Fate Therapeutics Appoints Laura Hamill to Board of Directors

SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immu... Full story

Yahoo Finance • last month

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immu... Full story

Yahoo Finance • last month

Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off

[Health Care sector, stock exchange monitor with index information.] Torsten Asmus The semi-annual rebalancing of U.S. equities is officially underway after FTSE Russell unveiled its preliminary list of shifts for the broad-market Russell... Full story

Yahoo Finance • 2 months ago

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE Patients; durable B cell remodeling is exhibited by depletion of major B cell clones up to 12 months following... Full story

Yahoo Finance • 4 months ago

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí B... Full story

Yahoo Finance • 5 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis r... Full story

Yahoo Finance • 7 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... Full story

Yahoo Finance • 8 months ago

Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact

This article first appeared on GuruFocus. Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing Warning! GuruFocus has detected 9 Warning Signs with ABBV. Is ABBV fairly valued? Test your thesis with our... Full story

Yahoo Finance • 8 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No Con... Full story

Yahoo Finance • 8 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favora... Full story

Yahoo Finance • 11 months ago

Fate Therapeutics’ SWOT analysis: biotech stock navigates clinical progress amid financial challenges

Fate Therapeutics, Inc. (NASDAQ:FATE), a biotechnology company specializing in programmed cellular immunotherapies for cancer and immune disorders, is navigating a critical juncture in its development pipeline. With a market capitalization... Full story

Yahoo Finance • 11 months ago

FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss

FATE THERAPEUTICS INC (NASDAQ:FATE [https://www.chartmill.com/stock/quote/FATE]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The clinical-stage biopharmaceutical compan... Full story

Yahoo Finance • 11 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus ery... Full story

Yahoo Finance • 11 months ago

Fate Therapeutics CEO Valamehr sells $15,396 in stock

Fate Therapeutics Inc (NASDAQ:FATE) President and CEO Bahram Valamehr sold 14,466 shares of common stock on August 4, 2025, according to a new SEC filing. The transaction comes as the stock has experienced a 9.4% decline over the past week... Full story

Yahoo Finance • last year

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5

Investing.com - H.C. Wainwright has reiterated its Neutral rating and $5.00 price target on Fate Therapeutics (NASDAQ:FATE), currently trading at $1.14, following the company’s presentation of FT819 data in lupus at the European Alliance o... Full story

Yahoo Finance • last year

Fate Therapeutics' SWOT analysis: promising data boosts stock outlook

Fate Therapeutics, Inc. (NASDAQ:FATE), a biotechnology company specializing in cellular immunotherapies, has been making significant strides in the development of treatments for cancer and autoimmune disorders. Recent clinical data and ana... Full story

Yahoo Finance • last year

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immuno... Full story